Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators.
Webster KA, O'Connor ML, Hansen AR, Kircher S, Jim HSL, Dicker AP, Janda M, Ala-Leppilampi K, Bingham CO 3rd, Feliciano J, Lynn Henry N, Steffen McLouth LE, Cella D. Webster KA, et al. Among authors: hansen ar. J Cancer Metastasis Treat. 2020;6:8. doi: 10.20517/2394-4722.2019.38. Epub 2020 Mar 13. J Cancer Metastasis Treat. 2020. PMID: 34790879 Free PMC article.
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J. Hansen AR, et al. Cancer. 2020 Apr 1;126(7):1550-1558. doi: 10.1002/cncr.32692. Epub 2020 Jan 8. Cancer. 2020. PMID: 31914209 Free article.
Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, Abdul Razak AR, Joshua AM, Hogg D, Bedard PL, Leighl N, Oza AM, Parsons JA, Hansen AR. Ala-Leppilampi K, et al. Among authors: hansen ar. Cancer Med. 2020 May;9(9):3015-3022. doi: 10.1002/cam4.2940. Epub 2020 Mar 2. Cancer Med. 2020. PMID: 32119767 Free PMC article.
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Janse van Rensburg HJ, Liu Z, Watson GA, Veitch ZW, Shepshelovich D, Spreafico A, Abdul Razak AR, Bedard PL, Siu LL, Minasian L, Hansen AR. Janse van Rensburg HJ, et al. Among authors: hansen ar. Br J Cancer. 2023 Sep;129(4):612-619. doi: 10.1038/s41416-023-02307-w. Epub 2023 Jul 7. Br J Cancer. 2023. PMID: 37419999 Free PMC article.
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A. Kanjanapan Y, et al. Among authors: hansen ar. Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529898
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL. Kanjanapan Y, et al. Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15. Cancer. 2019. PMID: 30768786 Free article.
272 results